辉瑞Sigvotatug Vedotin启动III期临床 适应症为PD-L1高表达的非小细胞肺癌

新浪财经
Aug 28, 2025

药物临床试验登记与信息公示平台数据显示,Pfizer Inc./ 辉瑞投资有限公司/ BSP Pharmaceuticals S.p.A.的一项在PD-L1高表达(≥ 50% 的肿瘤细胞表达PD-L1)、局部晚期、不可切除或转移性非小细胞肺癌研究参与者中评估Sigvotatug Vedotin与帕博利珠单抗联合治疗相比帕博利珠单抗单药治疗作为一线治疗的开放性、随机、对照III期研究已启动。临床试验...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10